Although Latin America offers substantial business opportunities for companies, it is a volatile region in economic terms. There is considerable risk involved in investing in the region and companies need to be fully aware of past economic crises and their causes before becoming involved.
Latin America continues to be a region of promising opportunities for commercial pharmaceutical organisations. The region represents a growing consumer base for the drug industry as by 2020 the regional population may be as high as 687 million.
The Latin American pharmaceutical market is now worth $45bn and multinational companies consider success in Brazil and Mexico as essential.
Healthcare & Pharmaceuticals in Latin America - A guide to the markets and regulations provides an excellent overview of the healthcare and pharmaceutical market in 19 Latin American countries.
This 40,000 word report, from URCH Publishing, will provide the reader with an excellent review of the healthcare systems, politics, regulatory framework, major companies and key issues affecting the healthcare sector.
Some of the main issues concerning pharmaceutical companies operating in the region include:
Intellectual Property: Laws on intellectual property remain weak or are not enforced in a number of countries, leading legally ambiguous products on the market.
Generics: Regional governments are making serious attempts to encourage the use of generics (in the past the term bioequivalence was interpreted differing across countries) and Indian companies in particular have made headway into the major markets.
R&D: Companies are finding Latin America an attractive centre for R&D. There are currently an estimate 4,000 clinical trials being conducted. High enrolment rates, lower labour costs and improving regulation have estimated the growth in outsourcing.
Political Situation: Unsettling for multinational companies is the political shift to the left in some countries. However, a number of countries are working to introduce universal healthcare coverage which in turn could create excellent long term opportunities.
Key features of the report:
Overview of healthcare systems in 19 Latin American countries
Review of the pharmaceutical market and major companies operating in each country
Brief guide to the relevant regulatory structure with comment on intellectual property issues.
Evaluation of the role of the generics in the domestic market
This report can help you:
Review the key political and government structures that influence business in the region
Understand the distinct characteristics of the Latin American pharmaceutical market
Consider how increased democracy will affect healthcare systems in relation to inequality and essential medicines
Gain insight into how generics are being promoted by a number of governments
Plan market strategy for successful entry and operation in the region